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Available online 8 April 2014Research on early diagnostics for Alzheimer's disease is supported by what has been labeled as
aging-and-innovation discourse, in which innovation is assumed to (partially) resolve the societal
problems related to aging. This discourse draws on a specific way of understanding Alzheimer's
disease and ways to deal with this condition, namely a biomedical model of Alzheimer's disease,
making the socio-cultural dimensions of Alzheimer's disease and aging less visible. In this paper we
further scrutinize the various meanings of this innovation by analyzing how it is intertwined
with different ways to define Alzheimer's disease and strategies to deal with it. We investigate
interpretative packages in two distinctly different settings: a health technology assessment (closely
related to the current research on early diagnostics) andAlzheimer's Cafés (where patients and their
family meet). Eleven interpretative packages summarize the scope of ongoing deliberation in these
two settings. By comparing and contrasting these interpretative packages we are able to better
characterize how new health technologies are accompanied with definitions of the problem and
forecasts of the future. We conclude that these interpretative packages about early diagnostics are
lessmonolithic and host a variety of different, sometimes conflicting definitions of early diagnostics,
the problem of Alzheimer's disease and its multiple futures.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/3.0/).Keywords:
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A central assumption in policy circles and research funding
is that scientific research and technological innovations
provide answers to societal challenges of aging. This is also
the casewith innovation in the field of Alzheimer's disease. The
argument is that due to an aging population the number of
persons with Alzheimer's disease will increase drastically in
the coming years and that thiswill lead to huge problems in the
health care system and the economy. This crisis account of
aging [1,2], is then turned into a major societal ‘challenge’ to be
addressed by innovation. This way of reasoning has been found
in general in relation to issues of aging and has been typified as
the ‘aging-and-innovation discourse’ [3]. Early molecular diag-
nostics is one of the key innovations positioned as a step towards, h.vanlente@uu.nl
r Inc. This is an open access arthe (partial) solution, for example in the Dutch ‘Deltaplan
dementia’ [4], the EU ‘Joint Planning Neurodegenerative Disease
Research Strategy’ [5] and the US ‘Alzheimer's Disease
Neuroimaging Initiative’ [6].
Early diagnostics here refers to both the possibility of an
earlier diagnosis and the specific technologies to achieve
this. The possibility of an earlier diagnosis can refer to different
situations: an early diagnosis of dementia (as a cluster of
symptoms and signs), a diagnosis of thepathology of Alzheimer's
disease in a pre-dementia stage, as well as the diagnosis of
Alzheimer's disease before any signs are present at all (called the
asymptomatic stage) [7]. The specific technologies of early
diagnosis are MRI scans, PET scans, and biomarker analysis.
The discourse and the underlying biomedical model have
been criticized by many scholars in the past decades.
According to the biomedical model, Alzheimer's disease is a
condition of a person, caused by deterioration of the brain.
Consequently, the way to deal with dementia is by medicalticle under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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be diagnosed, managed and treated by medical authorities.
The biomedical model has been critiqued for neglecting the
social components, thereby affecting choices in policy and
research, and having negative effects on the experience of
livingwith dementia. Claudia Chaufan [8], for instance, showed
how Alzheimer's disease as we currently know it has actively
been constructed as a medicalized condition with a biomedical
model of dealing with it. This “excludes alternative problem
definitions” and has led to a “triumph of cure over care” in
policy domains. In the same vein, Ingunn Moser [9] studied
how Alzheimer's disease has been made to matter in different
locations, amongwhich parliamentary politics. She argued that
“pharmaceutical and biomedical versions of the disease [are
made] present, visible, strong and dominant”, and alternatives
are “made absent, invisible and less real” (pg 107). Care is not
positioned as an alternative way of dealing with the matter,
rather it is turned into ‘doing nothing’, an (expensive) option of
last resort [9]. The prevalence of a biomedical model of
Alzheimer's disease does not only affect policy, politics and
division of resources, but is also critiqued for having negative
consequences on the experience of living with dementia and
on dementia care [10]. In reaction to the biomedical ‘cure
model’, ‘care models’ emerged from the 1990s onward, with a
main interest in the experience of persons with dementia, social
settings and relationships. Thomas Kitwood is, for example, one
of the pioneers of alternativemodelswith his approach of person
centered care [11–13]. He developed a broader framework for
the understanding of dementia, not only including neuropathol-
ogy but also social psychology,with the aim to provide good care
and a better life for persons with dementia.
So, ‘cure’ and ‘care’ have appeared as two strategies to deal
withAlzheimer's disease,with different overarching discourses
and logics. In these critiques cure is defined as (aiming for)
medical treatment, and care as ‘alternative strategies’, includ-
ing provision of physical, practical, emotional and spiritual
support. ‘Cure’ is often positioned as an ‘oppositional construct’
to argue the benefit of alternative approaches”, [14] in [15] p.3.
This positioning of cure versus care suggests that a choice
needs to be made between a cure or a care approach: should
one try to banish Alzheimer's disease from existence by
investing in research to understand the causes of dementia
and find a medical treatment, or should one search for the best
ways to live with Alzheimer's disease and find ways to support
patients and informal caregivers? In the cure versus care
opposition, the prospect of early diagnostics becomes prob-
lematic. And when the underlying logics of cure and care are
presented as opposites, a stalemate looms.
In this paper we investigate the various meanings of early
diagnostics in society, and analyze how this is intertwined with
different ways to define Alzheimer's disease and strategies to
deal with it. The ongoing discourse on early diagnostics for
Alzheimer's disease evolves and changes over time, and provides
diverging meanings and interpretations for relevant events. A
researcher may encounter all kinds of devices, like metaphors,
images, arguments, and moral appeals. These different elements
are not encountered as individual items, but they come in
clusters, and are organized around a central organizing idea, and
thus provide different, what Gamson and Modigliani refer to as,
‘interpretative packages’ [17]. We conceive discourse on early
diagnostics for Alzheimer's disease as a set of interpretativepackages, which make sense of early diagnostics. Distinguishing
a set of interpretative packages creates room for a range of
positions, rather than one overarching discourse, or two
competing discourses. We scrutinize the meanings and assump-
tions by investigating interpretative packages related to early
diagnostics and Alzheimer's disease. We define interpretive
packages as clusters of topics, arguments, and concerns that are
articulated recurrently in relation to the innovation and thus
create a web of understanding, through which is made sense of
this innovation.
We analyze these interpretative packages in two distinctly
different settings where problems, solutions and futures are
defined. The first setting, a health technology assessment project,
is closely related to the research on early diagnostics, which can
be typified as mainly a ‘cure’ context. The second setting,
Alzheimer's Cafés, where patients and their family meet,
provides contrasting ‘care’ perspectives and assessments of the
disease and theways to copewith it.We draw on literature from
STS as well as from dementia care to unravel the different ways
to deal with Alzheimer's disease and aging.
2. Theory: Alzheimer's and storytelling
The concepts ‘dementia’ and ‘Alzheimer's disease’ have a
turbulent history of contestation. During the last century, the
concepts have been the “product of complex negotiation between
awide number of interested parties – including patients, caregivers,
physicians, researcher, corporations, and policy makers – who
all have a stake in how we perceive, name, and respond to
illness.” p. 1 [16]. Contestations continue about how to define
Alzheimer's disease and how to deal with it (see e.g. [10,11,18]).
Is Alzheimer's disease a disease, or part of normal aging
(e.g.[18,19])? What are the causes of the symptoms of
Alzheimer's disease? It appears that persons with severe brain
damage can experience little symptoms and the other way
around. How can this be explained? And can changed behavior
be considered to be the result of neurological deterioration, or to
be the interplay between neurological impairment, physical
health, and psychological and social factors [11]?
There are different ways to distinguish conceptualizations of
dementia and ways to deal with it. The main theoretical models
that are currently distinguished are a biomedical model, a
psychosocial model, a disability model and a social gerontolog-
icalmodel [15,20,21]. The biomedicalmodel perceives dementia
as a pathological condition that should be diagnosed and
treated. It is characterized as an illness with progressive decline,
of which you should recognize the symptoms and gain insight
into the underlying causes. Since effective treatment is not
available yet, it is of utmost importance to develop effective
disease modifying treatment or preventative measures. A
psychosocial model and a disability model put the person
central and aim to increase the well-being of patients. The
psychosocial model focuses on the consequences of dementia
for individual persons with dementia and their caregivers. This
leads to attention to the experience of the personwith dementia
and the strategy to adjust care and support, to better cope with
this condition [15,22]. The disability model of dementia focuses
on the irreversible limitations to the functioning of a person.
These limitations or disabilities in daily functioning, ask for
structural adjustments to rehabilitate and stimulate the person
and for aids to keep persons functioning independently at a
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approach critiques the notion that elderly are a burden to society
and deplores their social exclusion. It pushes the idea that life
with dementia can remain fulfilling and points to thewider social
and structural factors that shape the experience of dementia [15].
In current practices these different models do not exclude
each other; they co-exist and relate to each other. Downs [20]
speaks about an eclectic use of different models. As we
recalled above, Moser stresses the politics at work in: how in
certain contexts some modes-of-ordering are made visible,
more real, and others are neglected, made invisible. And in
her book The Body Multiple Annemarie Mol [23] describes
how in different practices, illnesses are ‘done’ differently, or,
in her terms, ‘enacted’. For example, arteriosclerosis in the
consulting room with a patient is something else than the
entity derived from X-ray pictures of a radiologist. Also Innes
and Manthorpe stress that “How we approach dementia (…)
will impact on how we ‘see’ the problem; how we might try to
approach it; and how we might try and respond to or look for a
solution.” p. 8 8 [15]. It influences how not only professionals
in health care, but also policy makers, persons with dementia,
their caregivers and others respond to the challenges
dementia poses on them. Innes and Manthorpe also note,
however, that underlying assumptions and motivations are
often implicit, blurred andmultiple. The intricate relationship
between the different versions and representations of
Alzheimer's disease and the way to deal with it, is a central
lesson of studies of medical practices in science and
technology studies (STS).
Practices of dealing with a condition such as Alzheimer's
disease are thus somehow structured. Annemarie Mol, for
example, argues that medical practices are structured through
ideals, such as the ideal of patient autonomy (the ‘logic of
choice’) or through ideals of ‘good care’ (the ‘logic of care’). These
different ideals bring along “a specific mode of organizing action
and interaction, of understanding bodies, people and daily lives, of
dealingwith knowledge and technologies, of distinguishing between
good and bad, and so on.” p. 8 [24]. In her study of nursing homes,
Moser emphasizes the performativity of ‘modes-of-ordering’:
they make some responses or actions in a specific situation
more appropriate, more logical, than others [25]. Different
modes-of-ordering (she distinguishes a somaticing and a
relational mode-of-ordering) shape how dementia is enacted
upon, and along with this, shape the care for dementia, and the
way of living and dying with dementia. Hence, there are more
‘worlds-in-progress’, while in different locations some might
prevail different modes-of-ordering co-exist.
The meaning of early diagnostics for Alzheimer's disease
as a way to deal with Alzheimer's disease in aging societies, is
interwoven with the different understandings of Alzheimer's
disease and ways to deal with this condition.
As an entrance to study the meaning of early diagnostics,
and the connections beingmade between early diagnostics and
ways of approaching and dealing with Alzheimer's disease we
investigate the arguments, anecdotes and other stories that are
shared and circulate in settings where Alzheimer's disease and
early diagnostics are a topic of conversation. Storytelling is the
way in which humans construct and make sense of the world
around them and their own action [ 26–28]. Through stories
meaning is created and shared. Stories create ordering by
connecting different elements to a central purpose.3. Methods
The central question of this paper is how the development
of early diagnostics for Alzheimer's disease is entangled with
specific definitions of Alzheimer's disease and articulations of
problems and solutions in dealing with Alzheimer's disease
in the (near) future. We do this by analyzing the various
meanings of early diagnostics in two very different settings.
We investigate themeanings by distinguishing the ‘interpre-
tative packages’ in the stories that are being told in different
settings. We define interpretative package as a cluster of
recurring topics, arguments, and concerns (thus different
elements). These interpretative packages capture some aspects
of early diagnostics in an ordered mode of understanding. They
provide “webs of understanding” [29] to make sense of early
diagnostics in a setting. Depending on the stakeholder, the topic
and the kind of conversation, different interpretative packages
can come up. These interpretative packages are constitutive for
stories as they form a repertoire, which is available about early
diagnostics. In different settings the repertoires may differ and
some interpretative packages aremore exotic to one setting than
to the other. So interpretative packages are recognizable and
recurring patterns of themes and elements that expose a web of
understanding behind the development of early diagnostics.
We have selected two settings for this analysis, where sense
is being made of early diagnostics and Alzheimer's disease
through a vivid exchange of stories between different stake-
holders. One setting can be considered to bemore cure-oriented
(a health technology assessment (HTA) working group within a
biomedical research program); the other as more care-oriented
(a series of Alzheimer Cafés in a Dutch city).
The HTA setting is part of research on early molecular
diagnostics of Alzheimer's disease in the Netherlands that is
taking place within the LeARN program (Leiden Alzheimer
Research Nederland), and is partially financed by the ministry
of Public Health. One of the conditions for this funding was
clinical and societal relevance of the research. Therefore, the
consortium devoted one work package to a health technology
assessment (HTA) to evaluate the clinical and economic value of
early molecular diagnostics. It inquires how different instru-
ments perform, how much it costs and how the quality of life
and health care costs change through the introduction of early
diagnostic tests. This assessment includes monitoring a cohort
of patients to measure the accuracy of different diagnostic
instruments and the quality of life, a panel to determine the
added value of these instruments in clinical decision making
and a model to assess the costs of health care consumed by
patients and their informal caregivers (with and without these
novel instruments). Medical professionals (neurologists, psy-
chiatrists, geriatrics, radiologists), chemical analysts, and health
economists work together and exchange knowledge and ideas.
Here we expected to find cure-related accounts with a medical,
or evidence based approach to dementia.
The second setting is the Alzheimer Café. Alzheimer Cafés
are monthly informal events for persons with dementia, their
partners, family members, caregivers and other interested
persons. They provide a space and time for the visitors to
informally exchange ideas, information and experiences, and
to provide support to individual persons with dementia or
their relatives to help them deal with the situation. The
Alzheimer Café was initiated in The Netherlands to tackle the
Table 1
Data sources for HTA.
Interview with Work Package leaders (1, 2, 3, 4)*
PhD students working on the HTA (5,6,7)*
Discussion meetings (8,9)*
(Draft) articles (10, 11)
Extended Work Package description (12)
*In collaboration with Anna Laura van der Laan.
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within families [30]. The concept of the Alzheimer Café
quickly diffused across the Netherlands. Currently there are
over 180 Alzheimer Cafés and their number is still growing.
Also in other countries, such as the UK, the Alzheimer Café
example is being followed [31]. The formal goals of Alzheimer
Cafés are to educate, to speak openly about the problem, and to
recognize and emancipate patients and family members. Every
meeting lasts about 2 h and is organized around a theme (such
as causes of dementia, dealingwith dementia, communication)
and led by a moderator [32]. Attendants of Alzheimer cafés
consist of patients, their husbands, wives, friends, relatives,
informal caregivers, volunteers, persons who are worried that
they or somebody close to them is developing dementia,
nurses, pastors, caretakers, municipality officials, general
practitioners, and other local professionals. Everybody brings
along their own experience, questions and knowledge on
dementia and the way to deal with this condition. In this
setting we expected to find care-related, person-centered and
experience based accounts of Alzheimer's disease.
In both settings we collected different types of documents:
reports, interview transcripts, articles, books, educational
material, and notes and transcripts gathered through partici-
pant observation (See Tables 1 and 2). This diversity of data
sources provides a rich pool of arguments, anecdotes and
stories. We analyzed our documents with the following
research steps. We first separated phrases (text blocks) that
express (a) the role of early diagnostics (b) what Alzheimer's
disease is and (c)what the futurewill bring and how to address
it. Within this collection of phrases we labeled themes, such asTable 2
Overview of studied Alzheimer's Cafés.
Date Theme of Café
April 2010 Dementia in different phases (13)
May 2010 Forgetfulness or dementia? (14)
June 2010 Early diagnosis (15)
November 2010 Film screening (16)
January 2011 Dementia and existential questions (17)
February 2011 Behavioral problems and dementia (18)
March 2011 The role of the general practitioner (19)
April 2011 Daycare and daytime activities (20)
June 2011 Case management for dementia (21)
October 2011 Applying for care and help (22)
November 2011 Auxiliary service (23)
February 2012 Occupational therapy (24)
May 2012 Behavioral symptoms of dementia (25)
June 2012 Healthy living (26)
November 2012 Dementia for the immediate environment (27)‘stigma’ or ‘plaques in brains’ or ‘demographic trend’. We
investigated how these themes are connected in the docu-
ments. In this way, we could identify clusters of connections,
which we analyzed as different ‘interpretative packages’. Next
we summarized these different interpretative packages. The
last step was to check whether all themes and connections
were captured by the set of interpretative packages. For this
process of labeling we used ATLAS.ti software.
The analysis of the Alzheimer Cafés is based on observations
during Alzheimer Cafés in one region in the Netherlands from
April 2010 until November 2012. During these cafés, the first
author was allowed to make notes. Next to observing she also
engaged in conversations with the visitors, and took on a similar
role as volunteers of the Alzheimer Café. For background
information about the philosophy, and organization of the
Alzheimer Café she interviewed the organizers and participated
in a course for volunteers of the Alzheimer Cafés. During all these
occasions she made notes and transcripts.
While the analytical concern and themethodological steps in
both settings are similar, the emphasis differs due to the nature
of the settings. In the HTA setting early diagnostics and the
solutions it could provide are more central, while in the
Alzheimer Café setting, the emphasis is on dementia and how
to deal with it.
4. Results
4.1. Setting one: health technology assessment
Health technology assessment is a standardized practice
in health care to examine clinical, economic, societal and
ethical implications of technologies in health care. It is
intended as a bridge between medical research and policy
making. While others have analyzed and criticized the limita-
tions of the HTA approach (e.g. [32,33]), we consider this setting
as an excellent entrance to gain understanding about what kind
of solution early diagnostics provides, and how it is shaping and
being shaped by enactments of disease and theway to deal with
it. We could identify six interpretative packages of how early
diagnostics is entangled with representations of Alzheimer's
disease and how to deal with it. Our findings are summarized in
Table 3.
4.1.1. Early diagnostics as value for money
The first interpretative package in the HTA practice views
early diagnostics of Alzheimer's disease as a proposition
about costs and benefits. This interpretative package con-
cerns the efficient allocation of scarce resources in health care
and is embedded in health economics. It can be summarized
as follows.
“Health care is expensive and is getting more costly. New
technologies could potentially improve health care and increase
the quality of life for patients and informal caregivers, but may
also lead to an increase in costs. Therefore, it has to be examined
whether they are value for money. For early molecular
diagnostics it is not clear yet.”
This interpretative package centers on the advances made
in imaging techniques and the analysis of cerebrospinal fluid in
the past decade, leading to new and emerging diagnostic tests
based on biomarkers, which could improve the diagnosis of
Alzheimer's disease.
Table 3
Summary of interpretative packages in the HTA.
Setting 1: Health technology assessment
Meaning of early
diagnostics
Understanding of
Alzheimer's disease
What the future
will bring
How to address the
future — what should
be averted?
How to address the
future — what to
aim for?
Value for money Biomedical condition
Highly affecting well-being of
patient and informal
caregivers.
Societal burden
Increasing number of
persons with dementia.
Advances in imaging
techniques and biomarker
analysis.
More expensive
health care.
Decreased quality of life of
patients and informal
caregivers.
New cost-effective
medical technologies.
Decreasing societal costs.
Increasing quality of life.
Changing
health care
Biomedical condition
Measurable or visualizable
pathological changes in the
brain highly affecting quality
of life of patients and informal
caregivers.
Societal burden of increasing
health care costs.
Increasing number of
persons with dementia.
Advances in imaging
techniques and biomarker
analysis.
Maybe disease modifying
treatment.
Increasing health care costs.
Decreased quality of life of
patients and informal
caregivers.
Uncertain consequences of
early diagnostics in clinical
practice.
Improve diagnostic accuracy.
Increase health and well-being
of patients and informal
caregivers.
Decrease societal costs.
Assessments of consequences
of early diagnostics in clinical
practice.
Innovation
trajectory
Biomedical
Pathological changes in the
brain that can be measured or
visualized.
Application area for imaging
techniques and biomarker
tests.
Progress through innovation. Instruments to measure or
visualize changes in the brain
that signify Alzheimer's disease.
Implementation of best
technologies in clinical practice.
Changing
definition of
Alzheimer's
disease
Biomedical condition
Measurable or visualizable
pathological condition in the
brain.
Dementia syndrome
recognized by expression of a
cluster of symptoms.
Ongoing development of
imaging technologies and
biomarker tests.
Increased knowledge on
pathological processes
in the brain.
Updated diagnostic
guidelines.
Diagnosis based on
symptoms.
Better predict disease
progression.
Provide diagnosis at an
early stage, or predict disease,
based on neuropathology rather
than symptoms.
Change diagnostic guidelines.
Step on the road
to medication
Biomedical
A presently irreversible,
untreatable medical condition.
Development of disease
modifying treatment.
Lack of disease modifying
treatment.
A distressing disease course.
Far reaching consequences for
the quality of life of patient and
caregiver.
Progress in health care.
Speed up development of
disease modifying treatment.
Diagnose the disease in early phase
when medication is expected to be
most effective.
Early
management
Psychosocial
Untreatable condition.
Worry for persons with
memory complaints.
More and more technological
diagnosis.
Conducting a diagnosis as a
goal in itself.
Diagnosis (better information)
at a pre-dementia stage.
Provide certainty to worried
patients.
Better management of the
condition and patient in early
stages.
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benefit to patients and informal caregivers, they also contribute
to the rising costs of health care. The task, thus, is to consider
whether molecular diagnostic instruments have substantial
added value for the patient and their caregivers, and whether
they are cost-effective.
“Look, the whole reason why we are doing this research is
because it is not clear if you should use these markers in the
standard diagnostic procedure in the clinic or not.” (5) “The
HTA is about how much money you can put in to get how
much quality back. And about how much money you can
save by making an early diagnosis.” (1)
In this interpretative package, Alzheimer's disease is
considered as a disease that highly affects the well-being of
patients and informal caregivers, and places a substantial
burden on communities, given the rising number of personswith Alzheimer's disease in the near future, and the related
rising pressure on health care resources. According to this
interpretative package, it is of utmost importance to
validate these new tests, in terms of patient well-being,
costs, and on their additional value to current clinical
practice.
(Sources: 1, 2, 5, 10, 11, 12.)
4.1.2. Early diagnostics as having uncertain consequences for
(future) health care practices
A second interpretative package highlights the struggle
with the uncertainties of the (future) consequences for
health care practices, when newly developed early diagnostic
instruments are adopted: Howwould these tests improve the
accuracy of a diagnosis? What consequences does this have
on the quality of life of a patient and the informal caregiver?
What would be the consequences for health care costs?
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technologies are complex to assess. You first need to knowhow
they will change the possibilities for diagnostic and clinical
practice, and what it means for patients, informal caregivers
and the total costs of health care. It is a tremendous task, butwe
need to do it.”
In this interpretative package the focus is on the chain of
consequences to be measured and modeled in order to
determine the influence a test will have on health, well-being
and societal costs. This is a complex task involving many
uncertainties. “This is what we are after: what is happening
exactly? What is being done with information from these tests?
What does the whole process look like from adding a new test to,
ultimately, the health effects?” (8) To bridge the gap between
research and clinical practice a lot of information and assump-
tions are needed: the technical quality of the tests, the
performance in terms of sensitivity and specificity and
predictive value, the value of a test if added to other tests,
how this will change diagnostic decision making, how this
effects treatment and patient management, and how this will
affect health and well-being of patients and informal care-
givers, and eventually what the consequences are for societal
costs. With every step in this model uncertainties grow and
need to be dealt with. “When you add a different test, or change
the combination or sequence of tests, this will lead to a different
accuracy. The added value in accuracy can lead to different
decisions in care which will lead to a certain health effect and use
of means in healthcare (for example a decision to do follow up
tests).” (8)
In this interpretative package different pressing questions
are voiced. The central worry here is choices need to be made
aboutwhatwill be included and excluded in themodel before it
‘explodes of complexity’, as a researcher phrased it. Further-
more, tests need to have consequences for patientmanagement.
Since currently there is no disease modifying treatment, or care
program available yet for these patients, what will be the added
value for patient management? “What will be the consequences
for treatment?Which clinical decisions are taken based on the scan
results? You have to take into account the intervention options.
A test by itself does nothing. The most important is having
intervention options. And the cost-effectiveness depends on the
possibilities you have for that.” (9)
Another issue is that while these novel tests are being
assessed it is not yet clear what the outcome of a test means.
Whether these patients will really develop Alzheimer's
disease, and within what period, is part of this research and
is not known yet. “A: You might think it is malign to have a
positive scan result, but the question is what relevance this has.
If you say to a person: I am afraid you will function less well in
… the term becomes important. Is three years important? Is two
years important? (…) B: What is a useful outcome of test?
Everybody knows they will function less well in 20 years.” (8)
What to do with patients on whom you already conduct
these tests, and that have positive biomarker or imaging test
results, but show no deviation on neuropsychological exami-
nation? Should you tell them the results of the specific tests,
while it is not clear what these results mean? Andwhat do you
have to offer them, besides a follow-up appointment? “A: How
do you currently deal with subjective complaints? Persons who do
not have… (…) B: Sometimes it is being said that (…) the scan
suits their age. They are often elderly patients and they can havedeviations in the (…) scan without cognitive complaints. So we
communicate it like that. (…) A: (…) So whether it is positive or
negative, it is ‘suitable to the age’. So really it doesn't make a
difference? B: No, but it is the correct answer at this moment in
time. On which you could ask the question ‘than you shouldn't
apply for a scan’. And of course that is a little bit the field of tension
we are in now. Especially with subjective complaints. This is not
really a clinical… it is a research question.” (…) B: “So there has to
be a clinical indication for a clinical scan. That does notmean that I
think it is important for a patient to hear the full 100% information
from a scan, but I do think (…) it has to have consequences, even if
it is just to see a patient a bit earlier on follow-up, or not at all.” (8)
In this interpretative package, the task of HTA is to assess
the value of these novel tests in clinical practice, which
comes with the challenges of dealing with many uncer-
tainties that need to be faced.
(Sources: 5, 8, 9, 10.)
4.1.3. Early diagnostics as innovation trajectories
A third way to view the efforts to develop early diagnosis
of Alzheimer's disease is to position them as different
competing innovations. Summarized: “Progress in health
care is possible with innovation. Early diagnostics is an
umbrella term for various technological developments. They
are rooted in different sets of expertise. So, technologies have
their own trajectories and they compete.”
‘Earlymolecular diagnostics’ is an umbrella term for different
innovative techniques such as MRI and PET scans as well as the
chemical analysis of cerebrospinal fluid (CSF analysis). For these
techniques some tests are established and used in clinical
practice and a lot of them are still being developed. And for all
these techniques many different kinds of tests are developed,
focusing on different mechanisms related to Alzheimer's
disease, different biomarkers, different structural deviations in
the brain, or different ligands and radioactive labels (PET).
Within this interpretative package it is emphasized that
these specific tests are developed based on long-time experi-
ence and expertise in either PET, MRI or CSF analysis, of the
different medical centers that are involved. Not only are they
experienced in the application of existing tests, but also in
developing new diagnostic tests for neurological conditions.
Also past experience of industrial partners has informed the
choice for pursuing research on some specific biomarkers. Past
performance has been an important driver for the creation of a
new research program on early diagnostics for Alzheimer's
disease. These tests for Alzheimer's disease are part of build up
expertise in specific areas, and thus embedded in innovation
trajectories and research lines.
In this interpretative package, the development of early
diagnostics is considered as research and innovation, and
comes with many obstacles, drawbacks, unexpected results
and problems during the development. For each test that is
being developed there are long chains of steps that are
needed to actually have a test ready that could be evaluated
on its diagnostic value. Some tests turn out to be not good
enough; each test has its own strong points and weak
points.
A central argument in this interpretative package is that a
successful test, or combination of tests, could change the
diagnostic practice a lot. This could have far reaching
consequences. CSF analysis for example is relatively cheap
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send to a laboratory to be analyzed, which means it can be
easily implemented in current diagnostic practice. If PET
turns out to be the best, implementation is more complex
and expensive, since broad application would create the need
for PET scans in more hospitals, as well as facilities that can
produce the radioactive labels that are needed for the PET
scans.
(Sources: 1, 2, 3, 8, 9.)4.1.4. Early diagnostics as changing the deﬁnition of Alzheimer's
disease
A next interpretative package centers around the way
Alzheimer's disease is defined and diagnosed and how novel
technologieswill change this. “Weare nowcapable of diagnosing
Alzheimer dementia at an earlier stage, which changes the
notion of what it means to be diagnosed with Alzheimer's
disease. But also the basis on which a diagnosis is made is
shifting. The diagnosis of Alzheimer's disease used to be on the
basis of exclusion of other conditions. The importance of early
diagnostics is that it can show actual traces of Alzheimer's
disease in the brain. In this way, the whole notion of Alzheimer's
disease changes from symptoms to pathology. With early
diagnostics we can work on better definitions for research,
drug development and monitoring of patients.”
This interpretative package resonates with a long stand-
ing concern in research on Alzheimer's disease. Alzheimer's
disease is the most common form of dementia. Currently a
person is diagnosed with Alzheimer's disease when he or she
expresses the symptoms of dementia of the Alzheimer's type.
This is a so called ‘syndrome diagnosis’. MRI scans were
mainly meant to exclude other conditions. Within these
criteria the definite diagnosis Alzheimer's disease based on
pathology (based on depositions and accumulation of the
proteins amyloid and tau in the brain) could only be made
post mortem, based on biopsy and autopsy.
The emergence and ongoing development of brain imaging
technologies however, made it possible to study the changes
occurring in the brain due to Alzheimer's disease not only after
death, but during life. Early diagnostic instruments aim to
signal changes in the brain that can accurately predict if a
person will develop the symptoms of Alzheimer's disease or
not. This could shift the clinical diagnosis from a diagnosis
based on symptoms, to a diagnosis based on pathology during
life. “We can follow these parameters over time in a person. This is
revolutionary within the thinking about Alzheimer's!” says one of
the leading scientists (3). “I think in the future the bulk of the
diagnosis will be molecular diagnostics. Molecular imaging and
CSF analysis will eventually be a better predictor of the disease
than symptoms.”, says another leading scientist of the LeARN
program (1).
A good diagnostic test will have to be sensitive and specific.
However, most tests (also not the ones currently used) cannot
provide 100% certainty. A problem that occurs is that there is
no complete correlation between the development of specific
neuropathology and symptoms of Alzheimer's disease. There
are for example persons with cognitive complaints who do not
have amyloid plaques in the brain, and persons without
complaints who do. What should be decisive in a diagnosis in
those cases: the symptoms or the pathology?“C: And the question is how you look at Alzheimer's disease.
Do you call it Alzheimer's disease if somebody has clinical
symptoms, or if someone has Alzheimer pathology? A: That is
exactly the key question. (…) We cannot solve that now, you
could discuss about this endlessly.”(8)
“I think the whole idea; the whole thinking of Alzheimer's
disease will change. And the lay person should also realize
this. That is what we are already doing at the memory
clinics, we say to people: you have Alzheimer's disease. And
then they expect that they will be in a nursing home with a
diaper between their legs. And then we have to say: no, it
will not go that fast. Because in the old days we diagnosed
the condition in a much later stage. Nowadays we can do it
much earlier, in a milder stage, and for that reason it is so
important to support you so you can live a good life for
another ten years. So what you have been through with your
mother, exactly that we will try to… But of course it remains
a nasty condition, so you cannot go around that. But the idea
that there is nothing you can do is… Successful dementia for
example, well, ten years ago, you should not have come with
such an idea, and I think that now, it is well possible to
handle this handicap in successful ways. (…) I think the
general image of dementia, of Alzheimer, will have to be
adjusted. Because you are earlier with the diagnosis. So it is
not that when you hear the A-word, it means the end.” (1)
(Sources: 1, 2, 3, 5, 11.)
4.1.5. Early diagnostics as a step on the road to medication
Another interpretative package brings together diseases,
diagnosis and medication. “Early diagnostics should lead to
bettermedication. Progress in health care is about finding better
medication. When patients are diagnosed more accurately,
thematching of patients and drugs is better. Furthermore, an
early diagnosis enables treatment at an early stage when
medication is expected to be most effective. Even when
treatment is lacking currently, it is important to anticipate
its future availability.”
In this interpretative package it is stressed that Alzheimer's
disease is an irreversible disease with a distressing disease
course and far-reaching consequences on the lives of persons
affected by it, and that there is currently nothing that can be
done about it.Medically speaking, in the present andnear future,
receiving an early diagnosis is of no use for it does not lead to
specific treatment options. The ambition, therefore, is to make
sure persons have a better life and end of life, by developing
disease modifying treatment. “To optimize the benefits patients
can gain from treatment, installment early during the course of the
disease is desirable. However, AD is characterized by a long
preclinical course (accumulation of the histological changes
is estimated to precede clinical symptoms for as long as
15 years). Due to the lack of symptoms during the early phases
of the disease, early treatment will depend completely on
diagnostic tests that permit early diagnosis. Such tests are
currently lacking.” (12)
If there would be disease modifying treatment, this should
be provided to patients as early in the disease process as
possible, for instance in the stage of mild cognitive impairment
(MCI), when they do have memory complaints, but not yet
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dementia in 2, 3 or 10 years. So, prevention is even better
than cure. You cannot be too early to keep people healthy.
“A: If you talk about asymptomatic Alzheimer's disease, that is
the wrong way to go. You should not call that a disease. Maybe
an Alzheimer profile… but there is no benefit in labeling that a
disease. That is essential now. B: Yes because there is no
treatment. But that could be very different when there is a
treatment available.” (8)
In this interpretative package, early diagnostics and the
development of treatment go hand in hand. The question is at
what time from now a medical intervention will be developed.
“As soon as there are biological interventions possible, pills for
example, then things will change drastically. Everybody would like
to have a scan; therewill be amassive run on that. The question is at
what time from now that will happen. We have to be realistic,
because we have been saying that it will happen in 5 years for
25 years now.” (1)
Moreover, one cannot develop a good therapy without a
good diagnosis. “If you treat a population of patients with
anti-Alzheimer drugs, but 20% of these patients actually do not
have Alzheimer's disease, you will never find a medication
that can treat Alzheimer's disease.”, says one of the senior
researchers (3). A good diagnosis is needed to test new
medical treatments. And when a new treatment would
become available, diagnosis is of utmost importance to
provide it to the right patients.
So the importance of the development of early diagnostics
is to speed up the development of treatment and to provide
treatment to patients in an early stage. “This is what justifies
the whole research so far.” (3)
(Sources: 1, 2, 3, 12.)4.1.6. Early diagnostics as part of early management
This interpretative package addresses how early molecu-
lar diagnostics can benefit patients in the present, with no
disease modifying treatment available. “The quality of new
technologies for health care is determined by its benefit for
patients. Since there is no medication for Alzheimer's disease,
early diagnostic technologies have nothing to offer in terms
of cure. Instead, early diagnostics should be part of manage-
ment of the disease in early phases.”
This interpretative package contains the criticism that the
diagnosis seems to be becoming a goal in itself and does not
answer the questionwhat is the use of it for a patient. Scientific
research to make amyloid visible in a 7 Tesla MRI scan for
example, can bemeaningful in itself. “But if you translate this to
the interest of the patient, you have to be honest. Scientific insights
can be of interest for the patients, eventually. That is, for the
patient ‘in general’, not for the individual patient in the present.”
“You should not sell science as good patient care.” (1) For the
present patients, “It is not about the diagnosis, it is about what
you do with it. Early management, not early diagnosis. I think
there is too much focus on diagnostics as a goal in itself, which is
typical.” (1)
Currently a lot of tests are conducted to support a
diagnosis. These tests are synthesized by a physician who
will diagnose the patient, that is, when somebody already has
symptoms of dementia. But with early diagnostics, when the
symptoms are still subjective, persons are most worried,about whether this is just a temporary problem, or that it will
develop into a dementia.
In this interpretative package, the aim of early molecular
diagnostics is to provide better information at an earlier stage
of the condition, when patients can still understand and
comprehend the diagnosis and what it entails. It provides
possibilities for patients, informal caregivers, and professional
caregivers to better manage the condition: to timely make
plans, and arrange care and support. “There is a danger that the
care will be backgrounded. That a diagnosis becomes a goal in
itself, and that persons will not be supported enough afterwards.
So our plea is that a diagnosis should always be coupled to care.
You cannot put somebody in a scanner (…) and then say— yeswe
found it. It has to have consequences. You can already see this
happening as well. It will become more technological, but there is
also much more care available than 10 years ago: memory
training, education, informal caregiver support, Alzheimer cafés.
So these developments go hand in hand. This research program is
about the technical side.” (1)
(Sources: 1, 2, 3, 8, 9.)
4.2. Setting two: Alzheimer Café
The second setting we used is the Alzheimer Café.
Alzheimer Cafés are installed to help persons who are faced
with dementia to better cope with this condition. Many local
professionals attend these meetings, as well as patients, their
caregivers, family and friends, and persons who are worried
about dementia themselves, or that a loved one might be
developing dementia. This setting might not be the most
obvious place to learn about early molecular diagnostics. It is
a non-medical setting, and seems distant from technological
developments. Yet, here new technologies are on the horizon
as well, so it is an interesting setting to study to understand how
the development of early diagnostics is interwoven with
specific definitions of Alzheimer's disease and articulations of
ways to deal with Alzheimer's disease. In the discussions,
lectures and conversations in the Alzheimer Cafés we could
identify five recurring patterns of which we constructed the
following interpretative packages. Our findings are summa-
rized in Table 4.
4.2.1. Early diagnostics as identifying a biomedical condition
The first interpretative package relates to the understand-
ing of memory complaints as a foretoken of Alzheimer's
disease, which should be diagnosed by a doctor. “In case of
worries about forgetfulness, go and see your doctor. With
new diagnostic test a diagnosis can be conducted in an
increasingly early stage. Alzheimer's disease is a disease of
which forgetfulness is an important symptom. However, it is
not the only cause of forgetfulness, so it is important to find
out what is going on.”
In this interpretative package it is stressed that the most
well-known first indicator of Alzheimer's disease is forget-
fulness. Forgetfulness can have many underlying causes, like
depression, stress, normal aging, and use of alcohol, but it
could also be the first signs of dementia. The question is
when forgetfulness is the first sign of Alzheimer's disease. To
find out what the causes are of the complaints, a person can
go to a doctor or a memory clinic. “Alzheimer is a medical
Table 4
Summary of interpretative packages in the Alzheimer Cafés.
Setting 2: Alzheimer Café
Meaning of
early diagnostics
Understanding of
Alzheimer's disease
What the future
will bring
How to address the
future — what should
be averted?
How to address the
future — what to
aim for?
Identifying a
biomedical
condition
Biomedical
Progressive disease of
plaques and tangles in
the brain, that leads to
dementia.
Of which forgetfulness is a
foretoken.
Predict which patients
with subjective complaints
or mild cognitive impairment
will (not) develop dementia.
Late diagnosis.
Misunderstandings.
Unnecessary worries.
Early signaling and diagnosis.
Provide a prognosis, comfort,
prevent misunderstandings,
regulate risk factors, receive
available treatment, organize
care and support, plan life.
Part of good
patient
management
Psychosocial/disability
A disease with many faces.
Providing care and support
means searching and trying
what suits these persons in
this situation. There are
hardly ever real solutions.
Exhaustion of informal
caregivers.
Crisis situations.
Unnecessary suffering.
Timely provision of care
and support that suits these
persons in this situation.
Adapt life to the new
prospects.
Improve coping with the
condition.
Improve daily life. Enable
staying at home as long as
possible.
Attributing a
(socially significant)
label to a person
Social gerontological
A culturally laden label.
A taboo.
Diagnosis at an
increasingly early stage.
Mismatch between social
perception and actual functioning
of a person.
Taboo.
Stigma. Disqualification
or social exclusion of persons
with Alzheimer's disease.
A confirmation and
reassurance.
Foster understanding
about dementia.
Psycho-education.
Reduction of taboo.
Social inclusion.
A life event
putting things in the
‘Alzheimer
perspective’
Psychosocial/Life event
Certainty of a tragic fate.
A means to reinterpret past
events and to adjust life
plans.
Changed prospects on life.
A certain and continuous
process of far reaching loss
Increasing care responsibility
for close relations.
A paternalistic notion of
knowing what is good for a person.
A changed prospect on life.
Respecting coping
mechanisms of a person.
Know what you are up
against.
Recognition.
Reducing the
societal burden
Societal burden
Burden on health care
costs and health care system.
Biomedical/psychosocial
A need to provide timely
care and support to patients
and informal caregivers.
Increased number of patients
with dementia.
Increased health care costs.
Budget cuts in health care.
Worries about availability of
care and support in the near
future.
Misunderstandings.
Crisis situations.
Patients and informal
caregivers falling between
two stools.
Gap between an early
diagnosis and the access
to professional care and
support.
Timely signaling of signs of
dementia.
Timely organizing care and
support.
Availability of payable care
and support.
Delayed uptake in nursing
home/stay at home longer.
Increased use of social
network of patients to
provide care and support.
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dementia, but you can speak of mild memory problems, which
in some cases will lead to dementia. It is difficult to interpret.
Also other complaints can be a foretoken of dementia, such as
changes in character or behavior. This depends on the type of
dementia.” (14)
In a memory clinic a set of tests will be conducted to
distinguish if complaints of the patient or his/her relatives
might be related to normal aging,mild cognitive impairment (a
gray area of more complaints than can be related to aging, but
less than dementia), or dementia. And what the underlying
disease process is (Alzheimer's disease, vascular dementia, or
something else). “The more research with scans progresses, the
better they can distinguish one dementia from another.” (20) The
patients receive a diagnosis: ‘you are overly worried, you
function very well’, ‘you have normal forgetfulness related to
aging’, ‘we understand you are worried, it is not completelynormal, but the complaints are not severe enough to speak
about dementia’ or ‘you have dementia of a certain type’.
“Often persons visit the memory clinic who are needlessly
worried. There is so much information about dementia, that
this leads to fear (…). Forgetting something is normal when
you age. Forgetting the name of your grandchild once is
normal, as forgetting a card in a game of bridge once in a
while.” (19)
In this interpretative package the importance of an early
diagnosis is to provide a prognosis, to comfort persons that are
overly worried, to prevent misunderstandings, to regulate risk
factors such as high blood pressure, and to provide treatment
with the medication that is available. For good management of
this condition, it is important that after a patient has received a
diagnosis, (s)he moves into a care trajectory.
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uncertainty and lack of knowledge concerning the causes and
mechanisms involved in Alzheimer's disease. Researchers all
over the world are working hard to better understand this
condition and to findways to stop or slowdown the progression.
Current research is aimed at early diagnosis: predicting which
persons with subjective complaints or with mild cognitive
impairment will develop dementia, and which won't. Scientific
research now conducted aims to improve these predictions.
Next to this a lot of research is directed at the development of
drugs to stop or slow down disease progression, but so far
nothing really works.
(Sources: 13, 14, 15, 19, 22, 23, 24, 25, 26.)4.2.2. Early diagnostics as early patient management
This interpretative package is about how patients and
informal caregivers can best cope with the changing situation
which comes with the gradual changes related to Alzheimer's
disease. “It is key that patients and informal caregivers make
sense of early signals of dementia and can adapt their life to
this new situation and related prospects. An official diagnosis
should support their understanding and provide entrance to
health care arrangements. The core issue of Alzheimer's
disease is how patients and caregivers can cope with it.”
“A lot has changed in the past decennia in the attitude
towards dementia. In the past people pretended as long as
possible that there was nothing to worry about. Dementia
was seen as a verdict, where there is nothing to be done
about. Now we want to know what is going on as early as
possible, to try to slow down symptoms and prepare for
what is ahead: disease wise, but also for the person and the
family, and make a support plan around that person and
family.” (19)
“Guest: What if mom does not want to see a general
practitioner? Speaker: That is a matter of collaborating. You
could for example try to go to a general practitioner with
other complaints and slip it in. You can also visit the general
practitioner yourself. A plan needs to be made. The worst
thing you can do is pretend that there is nothing going on.”
(19)
There are different organizations that offer their help to
find out what is going on and to make a plan of what is
needed to keep on functioning in your daily life and live
independently (e.g. the elderly welfare organization, or a
case manager). The argument is that a lot of support, care and
help are possible when faced with the prospect of dementia.
However, when coping with dementia and problems related
to dementia, there are hardly ever real solutions. Providing
good care involves searching and trying what suits the
persons involved and their situation.
Yet, there are so many rules, laws and administrative
procedures, that obtaining help is quite complex. For
reimbursement and access to the professional care and
support available, often a diagnosis dementia is needed.
This means that there is a need for a timely diagnosis — not
too late and not too early. A timely diagnosis means entranceto a care trajectory, precepts and guidelines and avoids that
the informal caregiver becomes exhausted.
“I talk to a couple before the café starts. The woman tells me
that she received a diagnosis Alzheimer two months ago. She
already knew she had Alzheimer's and had been to the
general practitioner, who would not refer her to a memory
clinic. Even her bridge partners knew it. She was not able to
play bridge anymore. She forgot all the cards. (…)
Eventually she went to another general practitioner who
send her to the memory clinic. There, the scan showed that it
really was Alzheimer's. The doctor (…) had fully understood
her. He had asked if she wanted to hear the diagnosis, and
she had said yes. It will make you calmer, the doctor had
said, and that was exactly the case. Now she has the
conﬁrmation that she is not crazy, and that she really has
Alzheimer, which she had expected all the time. Now, she
says she gets Exelon plasters and goes to a daycare four
times a weak. She looks optimistic and relieved. Her husband
looked like he was not as relieved as his wife. I asked him if
the diagnosis had also made him calmer. No, not really, he
said. I asked if things changed for him afterwards. Also not,
he replied. It is very difﬁcult at home. She is so aggressive. It
is very heavy.” (20)
In this interpretative package Alzheimer's disease is
portrayed as a disease with many faces. The disease
progresses differently in individuals. The specific symptoms
and the speed in which the disease progresses differ from
person to person. And different persons cope in different
ways with this condition. Some individuals may panic, some
accept it easily, and others are calm and even happy. To
organize good support and care for everybody involved,
timely signaling of problems and receiving a diagnosis is
deemed very important.
(Sources: 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27.)
4.2.3. Early diagnostics as labeling persons
In this interpretative package, the diagnosis Alzheimer's
disease is not as much seen within the medical or health care
domain, but in the social domain. “Now that Alzheimer's
disease is diagnosed at an increasingly earlier stage, the
mismatch between the public perceptions related to the
label dementia and the actual functioning of a person will
increase. A diagnosis Alzheimer's disease attaches a label
to a person. When this happens, it has various profound
social consequences.”
A diagnosis means that a person is labeled with a certain
condition. Alzheimer's disease is an attribute of a person
which not only identifies the disease a person has, but also
labels the whole person with this condition.
In the cafés it was articulated that this label can result in
different responses. Depending on the persons involved, a
diagnosis may come as a confirmation and reassurance and
reduces uncertainty and bring understanding. On the other
hand, a diagnosis can function as a stigmatizing label,
disqualifying a person, by for example when relatives start
talking in their place, or taking tasks of their hands. A woman
came to the café to share the positive experience she has with
the day care facilities for her mother, although “her mother
prefers not to speak about the dementia. She wants to function
64 Y. Cuijpers, H. van Lente / Technological Forecasting & Social Change 93 (2015) 54–67within normal life and she does not want to draw too much
attention to the symptoms of dementia.” (20) In a café about
early diagnostics, I ask the question whether the visitors
would like to have a diagnosis at an early stage. A response is
that you should consider what this is like for the patients. “I
am afraid to be set aside with a ‘label’”, says one of the visitors
of the café. (15) The facilitator responds that this is often the
case, but that this label can bring peace as well. “Without it
irritation may occur: “She forgot it again”.” (15) Symptoms of
dementia can be interpreted as slackness, inattentiveness or
unwillingness. To avoid the negative effects of a label in the
home situation, psycho-education is very important for the
patient and their close relations. They have to find the right
path together.
This interpretative package emphasizes that “because
there is a lot of attention for dementia and because of new
technological possibilities, people visit a doctor earlier and a
diagnosis Alzheimer's disease can be given at an increasingly
earlier stage of the disease progression. Because of that persons
who are diagnosed with dementia now are still capable of much
more than in the past.” (15) This means that the public
understanding of Alzheimer's disease might not coincide
with the functioning of a person who is diagnosed with this
condition. One of the aims of organizing Alzheimer Cafés is to
reduce this taboo, to talk about dementia, and to foster
understanding that persons with dementia are not crazy.
(Sources: 14, 15, 23, 25.)
4.2.4. Early diagnostics as a life event putting things in an
‘Alzheimer perspective’
In the next interpretative package, the knowledge of having
Alzheimer's disease that comes with a diagnosis, becomes an
important element in the story of the life of persons with
dementia and their close relations. “Being diagnosed as having
Alzheimer's disease is a life changing event. It requires a deep
existential response and changes a person's past and future. Do
you really want to know this in an early stage?”
Expectations about life change drastically and certainly
when diagnosed with Alzheimer's disease. Facing Alzheimer's
disease signifies facing a certain and continuous process of far
reaching loss for the patient and their close relations. Dementia
is a terrible disease and a tragic fate.
“I enter the café, it is still early and I join a lady who sits
alone at a table. She tells me her husband has been
diagnosed with early stage dementia recently. How was it
for you, to hear the diagnosis, I asked. Well that was a huge
shock. (…) We now know what is going on, but it also gives
other prospects. Not quite rosy. I just retired. I am 67. My
husband is older. But still…”(26)
In this interpretative package it is highlighted that
persons who are faced with this condition need to reconsider
the prospects on their lives, in the light of this dismal future
they are facing. “My husband has early stage dementia, which
was diagnosed 1,5 year ago at the memory clinic. When we
heard it, it felt like a verdict. And that is what it is. It feels like we
are having Alzheimer together. My husband is very open about
it; sometimes he says ‘I happen to have Alzheimer’. He also told
it to our children, his brothers, sisters and friends. It makes it
easier to talk about and also to make jokes about it.” (27)Close relations, who are faced with the great responsibil-
ity to provide informal care to the person with dementia, are
up against a huge and burdensome task, accompanied by
grief, anger, sadness, and feelings of guilt of falling short. Not
only the prospects on life are reconsidered, there is also a
move to look back to reconstruct ‘when it started’, and to put
past events in the light of this newly gained knowledge.
In this interpretative package, questions arise concerning
the desirability of these prospects on life at an early stage.
Would you like to know if you or your relatives are
developing dementia? And when? Are the little things mum
forgets and her restlessness when your father is not at home,
a first symptom of dementia? When your father has had
Alzheimer, will you also get Alzheimer?
For some patients the diagnosis comes as a recognition of
what they expected (or dreaded) and a relief that at least
now they know what they are up against. But there is also a
tendency to avoid such knowledge: “I would like to be ahead
of problems, but on the other hand, I would not want to know
either”. (14) Often persons deny changes and refuse to see a
doctor. Should the family respect this, or should they seduce
the person to see a doctor for his/her own good?
In our current health care system, the idea is that persons
should know what is wrong with them and that a person
should receive a diagnosis, honest and clear. This has not
always been the case. “Should everybody be told this ‘truth’?
Do we always have to tell? It is very understandable to deny as
long as possible that something is wrong.” says one of the care
professionals in a café. (16) Is it always good to tell the truth,
seen that reactions to a diagnosis differ greatly? Do you want
to face this truth early on, or live in ignorance (or denial) as
long as possible?
(Sources: 13, 14, 15, 16, 19, 20, 21, 22, 23, 25, 26.)
4.2.5. Early diagnostics as reducing health care costs
This final interpretative package relates to the reduction
of health care costs, which is necessary with the prospect of
the increasing number of persons with dementia and the
subsequent pressure this puts on health care and the
economic system. “A timely diagnosis can reduce health
care costs by preparing care givers and thus allowing patients
to stay home longer. In an aging society, patients with
Alzheimer's disease are a burden. Demographic trends will
run to financial and nursing limits.”
This interpretative package starts in a similar way as the
aging-and-innovation discourse: In the coming years the
number of persons with dementia will increase, while the
number of persons to be able to provide care will decrease.
This is because persons get older on average, and the baby
boomers are aging. A timely signaling of problems that may
be first signals of dementia is important, because this can
avoid misunderstandings and crisis situations, by timely
organizing support and care. A lot of care and support is
available at the moment. This enables persons to stay at
home longer, and reduces the need of expensive nursing
homes.
Some visitors of the cafés expressed the worry that they
do not want to be a burden for their children or society. This
is accompanied by worries about how long care and support
will stay available and payable, given the budget cuts in
support and care at home. “You have told us all about these
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this stay available, and for how long? Financially? With the
budget cuts? We read all about it in the newspapers. We cannot
afford it ourselves.” “I am really worried about the future.” A
care professional says “We are all searching to find the best
way within the budget cuts.” “But despite this, it is very
important that you keep asking for help when you need it. Do
not let rumors about budget cuts, or a decline of a help question
scare you off.” (22)
(Sources: 15, 16, 18, 20, 21, 23, 26.)
The table below summarizes the different interpretative
packages and how they are related to understandings of
Alzheimer's disease, what the future will bring and how to
address it. When in the understanding of Alzheimer's disease
one of the models of dementia is prevalent this is added in
the column on this topic. Next to these models (biomedical,
psychosocial, disability, social gerontological) we also found
the understanding of Alzheimer's disease as a societal
burden, as an application area of new technologies and as a
life event, which could not easily be related to the models
that were described in the introduction. Probably this is
because the original four models mainly evolved in relation
to patients, where in this article the innovation is central, and
thus other considerations come to play.5. Discussion and conclusions
Research on early diagnostics of Alzheimer's disease does
not only bring new findings and promising technologies, but
also introduces and reinforces particular definitions of the
problem and forecasts of the future. In this paper we studied
the various meanings of early diagnostics, how they are
related to understandings of Alzheimer's disease and to
strategies to deal with Alzheimer's disease in the future. We did
so by studying in two different settings: a health technology
assessment group and a series of Alzheimer Cafés.
First of all we can conclude that a broad variety of
articulations is present, in both settings. This finding is in line
with the literature on medical practice, which has stressed the
different ways in which diseases are represented, understood
and enacted.
Secondly, we found that, notwithstanding this variety, the
huge diversity of ideas appears to be clustered. We have
captured these as generic interpretative packages, which
provide webs of understanding of the meaning of early
diagnostics, related to what Alzheimer's disease is, and how
wemay envision efforts to deal with it in the future. A particular
understanding of the disease tends to be related to a particular
approach to cope with the situation, and with a particular idea
on what the contribution of early diagnosis could be. In total we
have described eleven interpretative packages, six in the setting
of HTA and five in the setting of Alzheimer's Cafés.
Thirdly, in the different stories (the research data) that
this analysis is based on, we found that in one conversation,
during one meeting, or in one interview, more interpretative
packages come up. So each individual interview or meeting
can be viewed as a string of interpretative packages that are
articulated. People move between different interpretative
packages. The interpretative packages can be considered the
‘beads’ and every story a unique necklace.While this clustering in eleven interpretative packages is a
huge reduction in itself, and they are simplified and purified
to some extent, our findings differ from earlier accounts
which stress two opposing views, or logics, of health care.
The first is a view which portrays a disease and its problems
as a biomedical puzzle, to be solved by medical interventions
and further medical research. The other, opposing view,
portrays a disease and its problems as a condition of a person,
to be dealt with through careful attention to the personal
situation of the patient and his or her family. The first pole
has been labeled as stressing ‘cure’, the second as stressing
‘care’. This bi-polar condition is unfortunate and distorts a
rich and sensible reflection on how to deal with diseases such
as Alzheimer's in an aging society.
Our findings, however, go beyond this dichotomy of ‘cure’
versus ‘care’. We did not find two logics at work, but eleven. A
division in ‘cure’ and ‘care’ and models of Alzheimer's disease
such as the biomedical, psychosocial, disability or social
gerontological model, are based on how to best support and
help patients and informal caregivers. However, we also
found interpretative packages about the competitiveness in
technology development and about innovations looking for
application areas in clinical practice, about shifting notions of
what is considered as normal aging and what is considered
pathological, an interpretative package about the aging popula-
tions and the increasing number of persons with dementia that
put a stress on the current economic and health care system, as
well as a interpretative package on expectations about life and
existential questions arising with a diagnosis Alzheimer's
disease. Within developments of early diagnostics more comes
to play, besides supporting or helping patients and informal
caregivers. Of course, when we would have chosen other
settings wemay have found less or more, or slightly different
interpretative packages. The basic lesson, however, is that
when stakeholders reflect on early diagnostics there will
be more than just two sets of positions, concerns and
understandings.
We found that the envisioned implications of early
diagnostics are entangled with cure and care strategies in
various ways. First of all, early diagnostics is said to contribute
to both the cure and care strategy, and thus making a cure
versus care discussion less relevant. The co-existence of both
approaches has been elaborated on before e.g. as co-existing in
memory clinics when dealing with early stages of dementia
[35] and in nursing homes [25]. Secondly, with a focus on early
diagnostics more comes to the fore than consequences for
patients, such as the organization of the health care system, and
medical research agendas. Furthermore people with a
diagnosis Alzheimer's disease are not mere patients, but
also persons with a life and a view on life. We claim that a
cure/care dichotomy brings along a narrow focus on how to
deal with dementia, which obscures other interests, such as
leading a fulfilling life, keeping a viable health care system,
scientific advancement, or innovative competitiveness. Such
considerations are equally important and should not be
backgrounded.
In terms of the aging-and-innovation discourse, our
analysis of interpretative package confirms that early diagnos-
tics for Alzheimer's disease is not a self-evident part of a
solution to the increasing number of persons with Alzheimer's
disease in aging societies, such as the Netherlands.
66 Y. Cuijpers, H. van Lente / Technological Forecasting & Social Change 93 (2015) 54–67The aging and innovation discourse mobilizes interpre-
tative packages on reducing the societal burden, it empha-
sizes the importance of early diagnostics as a step on the
road to medication, of identification of a biomedical
condition, of changing of health care and of early manage-
ment, and of progress through innovation. It leaves out how
exactly early diagnostics will become part of good patient
management, uncertainties about the value for money,
worries about budget cuts in care provision and reimburse-
ment, the uncertainties about the value of early diagnostics
while disease modifying is not yet available, the (social)
effects of the label Alzheimer's disease for a person, the life
event this signifies, and how this changes the definition of
Alzheimer's disease.
The two settings we studied provide richer accounts
than the aging and innovation discourse. Both settings
stress the importance of an early diagnosis as the
identification of the condition underlying symptoms such
as forgetfulness, as well as the need to timely provide care
and support. But the social gerontological approach and
the life event that a diagnosis of Alzheimer's disease
entails are absent from the health technology setting, just
like the discussion about the performance of specific
diagnostic instruments, and shifts in the definition of
Alzheimer's disease towards a more neuropathological
definition are absent in the Alzheimer Café. The two
settings thus seem to be complementary — a finding with
practical and optimistic consequences. Instead of a para-
lyzing stalemate between ‘cure’ and ‘care’, the under-
standing of the problems and the ways to address it will
have various overlaps. The theoretical and practical task
ahead, thus, is not to articulate the two positions of ‘cure’
and ‘care’ further, but to map the overlaps of interpretative
packages and thus to reconcile concerns and strategies.
Another, less optimistic, conclusion would be that some
interpretative packages are less visible, appropriate, or
maybe even silenced in the modes-of-ordering present in
these settings.
The richnesswe encountered, however, does not imply that
the tension between ‘cure’ and ‘care’ as two fundamentally
different modes of representing health care has vanished
completely. However we did not encounter ‘cure’ and ‘care’ as
two sets of parties that confront each other, or two bodies of
argumentation. The tension between care and cure does not
appear as two poles, but as a theme that submerges in many
different interpretative packages. The polarization only oc-
curred occasionally, when the allocation of research budgets or
the attraction of patients was discussed, the cure–care
opposition was used to mold the discussion and to mobilize
allies.
To conclude, we can expect that every narrative about
early diagnostics will mobilize some of these interpretative
packages in particular ways and will leave out others, as part
of politics, agenda-setting or the acquisition of resources by
stakeholders. Our study emphasizes that different ways of
approaching Alzheimer's disease are closely connected to the
way we ‘see’ the problem and respond to it, or look for a
solution. The explication of eleven interpretative packages
creates the possibility to identify which ones are mobilized
and which ones stay outside of discussions, arguments and
conversations, and thus can serve as a way to understand thepolitics at work and identify and detect overlooked issues
that should be included.
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